Format

Send to

Choose Destination
Indian J Pharmacol. 2015 Jul-Aug;47(4):444-6. doi: 10.4103/0253-7613.161274.

Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin.

Author information

1
University School of Biotechnology, GGS Indraprastha University, Dwarka, New Delhi, India.

Abstract

OBJECTIVES:

The brain of mammals contains two major form of cholinesterase enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The dual inhibition of these enzymes is considered as a promising strategy for the treatment of neurological disorder such as Alzheimer's disease (AD), senile dementia, ataxia, and myasthenia gravis. The present study was undertaken to explore the anticholinesterase inhibition property of allicin.

MATERIALS AND METHODS:

An assessment of cholinesterase inhibition was carried out by Ellman's assay.

RESULTS:

The present study demonstrates allicin, a major ingredient of crushed garlic (Allium sativum L.) inhibited both AChE and BuChE enzymes in a concentration-dependent manner. For allicin, the IC₅₀ concentration was 0.01 mg/mL (61.62 μM) for AChE and 0.05 ± 0.018 mg/mL (308.12 μM) for BuChE enzymes.

CONCLUSIONS:

Allicin shows a potential to ameliorate the decline of cognitive function and memory loss associated with AD by inhibiting cholinesterase enzymes and upregulate the levels of acetylcholine (ACh) in the brain. It can be used as a new lead to target AChE and BuChE to upregulate the level of ACh which will be useful in alleviating the symptoms associated with AD.

KEYWORDS:

Acetylcholinesterase; Alzheimer's diseases; allicin; butyrylcholinesterase

PMID:
26288480
PMCID:
PMC4527070
DOI:
10.4103/0253-7613.161274
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center